Navigation Links
EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
Date:6/3/2011

ROCKVILLE, Md., June 3, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.   The data were presented by the principal investigator for the study, Dr. Ursula A. Matulonis, medical director of gynecologic oncology at Dana-Farber Cancer Institute and associate professor of medicine, Harvard Medical School, during a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2011 in Chicago, Illinois.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

The trial was an open-label, single-arm, multi-center-study of ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer.  The study was conducted at six sites in the United States and Canada and included Dana-Farber Cancer Institute, Indiana University Melvin & Bren Simon Cancer Center, University of Chicago Medical Center, Memorial Sloan-Kettering Cancer Center, University of Colorado Cancer Center, and Princess Margaret Hospital.  Sixty-four patients were enrolled of which 57 were evaluable at the time of the presentation.  The primary endpoint for the study was progression-free survival rate at six months.  Secondary end-points include response rate, duration of response, and overall survival.  

ENMD-2076 demonstrated clinical activity when administered daily orally as a single agent.  Interim data from 57 evaluable patients showed a six-month progression free survival rate of 19%.  Of the evaluable patients, four patients achieved a partial response and 30 patients achieved stable disease as measured by RECIST v1.1.
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
2. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
5. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
6. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
7. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
8. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
9. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
10. Capasso lab demonstrates highly unidirectional whispering gallery microlasers
11. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)...  The element of surprise has been a major ... without warning. Until now, epidemiologists had nothing to measure ... resulting in suboptimal responses to both the H1N1 pandemic ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 That ... virus gene structural changes have been found that invariably ...
(Date:11/21/2014)... England , Nov. 21, 2014   TRU-D SmartUVC ... will feature their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, ... this week from Nov. 23 to 26 at Stand 23. ... is the United Kingdom,s largest infection-related ... infection prevention societies to one of the leading events of ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Author ... Short Walk to the Other Side” published as ... “Award-Winning Finalist in the “Fiction: Short Story” category of ... Jeffrey Keen, President and CEO of USA Book News, ... mainstream and independent publishers, including Simon & Schuster, Penguin, ...
(Date:11/21/2014)... New York, NY (PRWEB) November 20, 2014 ... ) is now available as an open access journal ... cells with infrared fluorescent proteins to preserve photoresponsiveness in ... Two-color fluorescent in situ hybridization using chromogenic ... microfluidics chips for DNA, RNA, and protein electrophoresis , ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3
... SUNNYVALE, Calif., Aug. 5 Pharmacyclics, Inc. (Nasdaq: PCYC ... up to 22,500,000 shares of the Company,s common stock at a subscription ... on July 31, 2009. The Company increased the offering size on July ... to 22,500,000 shares. , , The subscription ...
... JEFFERSON, N.C., Aug. 5 Next Safety, Inc. (NSI) ... work in a pandemic environment. Next Safety is releasing for sale ... flu influenza A subtype H5N1. , , The ... became contagious. The Next Safety respirators are now being sold to ...
... , SANTA MONICA, Calif., Aug. 5 Cord ... stem cell preservation company ( http://www.cordblood-america.com ) ... families nationwide and internationally, said today it has retired $2.53M of ... in February and March of 2007 respectively, between CBAI and the ...
Cached Biology Technology:Pharmacyclics, Inc. Rights Offering Oversubscribed 2Pharmacyclics, Inc. Rights Offering Oversubscribed 3Next Safety Releases Advanced Respirator for Infectious Diseases 2Next Safety Releases Advanced Respirator for Infectious Diseases 3Cord Blood America Retires $2.53M Obligation 2Cord Blood America Retires $2.53M Obligation 3
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2
... neuroscience research programme that spans basic science all the ... tertiary hospitals and medical schools, and a national organisation ... Singapore. These are some of the new initiatives ... Council (BMS IAC) at their annual meeting today. ...
... An international team of Australian and Israeli researchers has ... moonlight sex event on Earth., An ancient light-sensitive gene ... of Excellence for Coral Reef Studies (CoECRS) that appears ... spawning of corals across a third of a million ...
... method of constructing artificial plant chromosomes from small rings ... transport multiple genes at once into embryonic plants where ... passed on to the next generation -- a long-term ... In the October 19, 2007, issue of PLoS-Genetics, ...
Cached Biology News:Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 2Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 3Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 4Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 5Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 6Key found to moonlight romance 2Key found to moonlight romance 3Transgenics transformed 2Transgenics transformed 3
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Request Info...
Request Info...
Non-Protein Peroxidase Stabilizer , 1 L...
Biology Products: